Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

The PSMAddition trial shows 177Lu PSMA-617 significantly delays progression in mHSPC when added to hormone therapy, with a ...

Encorafenib and binimetinib show promise in reducing recurrence risk for high-risk BRAF V600-mutant melanoma, demonstrating a ...

A phase 3 trial did not support a transplant-based approach for patients who already achieved MRD negativity or a tandem ...

Adding CAN-2409 to standard radiation therapy significantly improved disease-free survival and pathological complete response ...

JNJ-79635322 shows favorable responses and manageable safety in BCMA/GPRC5D-naïve patients with relapsed/refractory multiple ...

Daratumumab enhances treatment efficacy in newly diagnosed multiple myeloma, showing improved MRD negativity and ...

Relacorilant/nab-paclitaxel significantly improved PFS and OS vs nab-paclitaxel alone in platinum-resistant ovarian cancer.

In an interview, Rana McKay, MD, discusses findings from the COMRADE trial evaluating olaparib plus radium-223 in prostate cancer presented at the 2025 ASCO Annual Meeting.

Vincent Picozzi, MD, discusses findings from the phase 3 trial PANOVA-3 of TTFields with gemcitabine and nab-paclitaxel in locally advanced pancreatic cancer.

Alicia Morgans, MD, MPH, discusses the phase 3 ARASTEP trial evaluating darolutamide in patients at high risk of biochemical recurrence of prostate cancer.